EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: Patient outcome, interplay with morphology and immunophenotype

Keyphrases

• Patient Outcomes 100%
• Immunophenotyping 100%
• Adenocarcinoma 100%
• KRAS mutation 100%
• Diagnostic Biomarker 100%
• Lung Adenocarcinoma 100%
• Epidermal Growth Factor Receptor Gene 100%
• Gene Alteration 100%
• BRAF Gene 100%
• ALK Gene 100%
• Hazard Ratio 66%
• Prognostic Biomarker 66%
• BRAF mutation 66%
• Clinically Significant 33%
• Clinical Parameters 33%
• Survival Prediction 33%
• Diagnostic Algorithm 33%
• Rodents 33%
• Multivariate Analysis 33%
• Female Sex 33%
• Overall Survival 33%
• Growth Pattern 33%
• Disease-free Survival 33%
• Prognostic Effect 33%
• Distinct Patterns 33%
• Non-smoking 33%
• Treatment Algorithm 33%
• Pulmonary Adenocarcinoma 33%
• Smoking History 33%
• Thyroid Transcription factor-1 (TTF-1) 33%
• Thymidylate Synthase 33%
• EGFR mutation 33%
• ERCC1 33%
• Adenocarcinoma Subtype 33%
• Cytokeratin 7 33%
• Failed Repair 33%
• Napsin A 33%
• ALK Rearrangement 33%
• Micropapillary Growth 33%
• Lepidic Growth 33%
• V-raf murine Sarcoma Viral Oncogene Homolog B1 33%
• V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog 33%
• Survival Parameters 33%
• Adjuvant Radiochemotherapy 33%
• Epidermal Growth Factor Receptor Inhibitors (EGFRI) 33%
• Complementation Group 33%
• Morphological Diagnostics 33%
• Male Smokers 33%
• Morphological Biomarkers 33%

Biochemistry, Genetics and Molecular Biology

• KRAS 100%
• Gene Mutation 100%
• Epidermal Growth Factor Receptor 100%
• Immunophenotyping 100%
• Morphology 66%
• Virus Oncogene 66%
• Multivariate Analysis 33%
• Ras2 33%
• Prevalence 33%
• Overall Survival 33%
• Disease Free Survival 33%
• Anaplastic Lymphoma Kinase 33%
• Excision Repair Cross-Complementing 33%
• Homeobox Protein Nkx 2.1 33%
• Thymidylate Synthase 33%
• Keratin 7 33%
• Diagnostic Biomarker 33%
• Deficiency 33%
• Rat 33%